Orchid Pharma

Orchid Pharma Limited reported quarterly sales of INR 173 crores compared to INR 244 crores in the same period last year, marking a 29% decline. The company attributed this performance to an unprecedented global slowdown in the antibiotics market, with both prices and volumes under pressure. Despite challenges, the company maintained gross margins at around 42% and operational EBITDA of INR 14 crores. In a significant development, Orchid acquired global rights to Enmetazobactam and trademark Exblifep from Allecra following the latter's insolvency. This acquisition gives Orchid complete control over regulatory and commercial strategy for the novel antibiotic worldwide, with double-digit royalties from Advanz in Europe now flowing directly to Orchid. The product is already licensed in Europe, Middle East, and North African markets through existing agreements. Management expects the antibiotics market challenges to persist through the current year, with no revival anticipated in the near future. The company's 7ACA project in Jammu continues as planned, and the Cefiderocol project remains on track for December 2026 launch.